References
- 1 Kuchuk M, Addison CL, Clemons M, Kuchuk I, Wheatley-Price P. Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol. 2013; 2(1): 22–9. DOI: 10.1016/j.jbo.2012.12.004
-
2
Reddington
JA,
Mendez
GA,
Ching
A,
Kubicky
CD,
Klimo
P,
Jr , Ragel BT. Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: Osteolytic versus osteoblastic. Surg Neurol Int. 2016; 7(Suppl 13): S361–S365. DOI: 10.4103/2152-7806.182549 - 3 Al-Nabhani K, Syed R, Haroon A, Almukhailed O, Bomanji J. Flare response versus disease progression in patients with non-small cell lung cancer. J Radiol Case Rep. 2012; 6(11): 34–42. DOI: 10.3941/jrcr.v6i11.1109
- 4 Bersanelli M, Bini P, Rabaiotti E, et al. Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: A potential blunder. Tumori Journal. 2017; 103(1): 66–71. DOI: 10.5301/tj.5000423
- 5 Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol. 1995; 13(5): 1123–8. DOI: 10.1200/JCO.1995.13.5.1123
- 6 Yu YS, Li WH, Li MH, Meng X, Kong LI, Yu JM. False-positive diagnosis of disease progression by magnetic resonance imaging for response assessment in prostate cancer with bone metastases: A case report and review of the pitfalls of images in the literature. Oncol Lett. 2015; 10(6): 3585–90. DOI: 10.3892/ol.2015.3753
- 7 Pluquet E, Cadranel J, Legendre A, et al. Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival. J Thorac Oncol. 2010; 5(4): 491–6. DOI: 10.1097/JTO.0b013e3181cf0440
- 8 Lind JS, Postmus PE, Smit EF. Osteoblastic bone lesions developing during treatment with erlotinib indicate major response in patients with non-small cell lung cancer: A brief report. J Thorac Oncol. 2010; 5(4): 554–7. DOI: 10.1097/JTO.0b013e3181d3e47e
- 9 Chao HS, Chang CP, Chiu CH, Chu LS, Chen YM, Tsai CM. Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib. Clin Nucl Med. 2009; 34(6): 346–9. DOI: 10.1097/RLU.0b013e3181a344df
- 10 Gelsomino F, Ambrosini V, Melotti B, Sperandi F, Ardizzoni A. Pitfalls in oncology: Osteoblastic response mimicking bone progression during ceritinib treatment in ALK-rearranged NSCLC. J Thorac Oncol. 2016; 11(8): e99–e101. DOI: 10.1016/j.jtho.2016.04.002
- 11 Normanno N, De Luca A, Aldinucci D, et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: Implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer. 2005; 12(2): 471–82. DOI: 10.1677/erc.1.00956
- 12 Zhang X, Tamasi J, Lu X, et al. Epidermal growth factor receptor plays an anabolic role in bone metabolism in vivo. J Bone Miner Res. 2011; 26(5): 1022–34. DOI: 10.1002/jbmr.295
- 13 Suzuki M, Shigematsu H, Nakajima T, et al. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2007; 13(20): 6087–92. DOI: 10.1158/1078-0432.CCR-07-0591
- 14 Emami KH, Corey E. When prostate cancer meets bone: Control by wnts. Cancer Lett. 2007; 253(2): 170–9. DOI: 10.1016/j.canlet.2006.12.040
- 15 Devarakonda S, Masood A, Govindan R. Next-generation sequencing of lung cancers: Lessons learned and future directions. Hematol Oncol Clin North Am. 2017; 31(1): 1–12. DOI: 10.1016/j.hoc.2016.08.008
- 16 Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020; 12(1): 8. DOI: 10.1186/s13073-019-0703-1